WASHINGTON, D.C. — The U.S. Department of Justice on Thursday announced a sweeping change to federal drug policy, reclassifying certain marijuana products under Schedule III of the Controlled Substances Act, marking the most significant shift in federal cannabis policy in decades.
Acting Attorney General Todd Blanche confirmed that FDA-approved marijuana products and state-licensed medical cannabis will no longer be treated as Schedule I substances — a category reserved for drugs such as heroin. “The Department of Justice is delivering on President Donald Trump’s commitment to expand access to medical treatment options,” Blanche said in a statement accompanying the decision.
The move signals a major recalibration in how federal authorities view cannabis, acknowledging its potential medical use while opening the door to expanded research and commercial activity. The administration also announced plans for an expedited hearing in June to consider broader reclassification of marijuana at the federal level, a step that could further reshape the industry.
Industry leaders and policy advocates quickly hailed the decision as a turning point. Adam Smith, executive director of the Marijuana Policy Project, described the shift as “a historic recognition that cannabis has accepted medical uses,” noting that federal classification had long lagged behind state-level legalization trends.
From a business perspective, the impact could be immediate. Irwin Simon, Chief Executive Officer of Tilray Brands Inc., said the reclassification will allow companies to engage more directly with federal regulators. “We now have the ability to present research to the FDA and DEA in a meaningful way,” Simon said, emphasizing the opportunity for expanded product development and regulatory clarity.
The change also carries significant financial implications. By moving to Schedule III, cannabis businesses may gain relief from restrictive tax provisions that previously limited deductions under Section 280E of the Internal Revenue Code. Analysts say this could materially improve profitability across the sector, particularly for multi-state operators.
However, the policy shift stops short of full federal legalization. Marijuana remains illegal under federal law for recreational use, and the reclassification does not affect existing criminal cases or individuals currently incarcerated for cannabis-related offenses. Legal experts note that broader reform would require congressional action.
The announcement has also exposed divisions within the political landscape. More than 20 Republican senators previously urged the administration to maintain stricter controls on cannabis, citing public health and safety concerns. The upcoming June hearings are expected to further test those divisions as policymakers weigh the long-term direction of federal drug policy.
For the cannabis industry, long constrained by limited access to banking services and federal research funding, the change represents a potential inflection point. Companies are now positioned to operate with greater legitimacy and fewer regulatory barriers, even as uncertainty remains around future policy developments.
What comes next will depend heavily on the outcome of the June review and the broader political environment. But for now, the federal government has taken a decisive step — one that could reshape an industry and redefine the legal framework surrounding cannabis in the United States.
JBizNews Desk
